title: Treatment with gefitinib after erlotinib-induced liver injury: a case report.
abstract: BACKGROUND
  Gefitinib and erlotinib have minor differences in their chemical structures, and thus it remains unclear whether the hepatotoxicity induced by one compound is affected by the other. The case of a patient who developed erlotinib-induced liver injury and was then treated with gefitinib without hepatic toxicity or disease progression is presented.
  
  
  METHODS
  A 31-year-old Japanese woman, who never smoked and who was diagnosed as having lung adenocarcinoma with carcinomatous meningitis, was treated with erlotinib. She developed erlotinib-induced liver injury after four weeks of treatment. The treatment was stopped right away, but the symptoms of meningitis re-appeared immediately. Gefitinib treatment was started and continued without recurrence of drug-induced liver injury.
  
  
  CONCLUSIONS
  Gefitinib appears to be a potential treatment option after erlotinib-induced liver injury.
authors.affiliation: Second Department of Internal Medicine, Nagasaki University School of Medicine, Nagasaki, Japan. yi-nakamu@umin.ac.jp.
authors.forename: Katsumi
authors.initials: K
authors.lastname: Nakatomi
authors.forename: Yoichi
authors.initials: Y
authors.lastname: Nakamura
authors.forename: Iida
authors.initials: I
authors.lastname: Tetsuya
authors.forename: Shigeru
authors.initials: S
authors.lastname: Kohno